Regulatory Pressure
ePRO Tech Trends
PHT discusses the growth in the acceptance of ePRO as a core technology.
Hedge funds have been making waves in the clinical development industry for years, snapping up contract research organizations (CRO) with publicly-listed shares and putting them in private hands. Now the game appears to be shifting to undervalued technology firms. Genstar finalized the $400 million purchase of ERT, the #1 cardiac core lab, earlier this month. This week, Genstar wrote a second check. For an undisclosed sum, the private equity group added a top electronic patient diary provider, Pittsburgh’s invivodata, to the ERT portfolio. Based in San Francisco, Genstar is no stranger to clinical research. It purchased PRA International for $790 million in 2007. Genstar isn’t telegraphing whether it is considering a potential combination of PRA and ERT. That move would mirror some of the assets at Parexel, which Wall Street does appear to understand. It may not be clear for years whether such a move would please customers in pharma (by…more...
At its annual customer conference last week in its home town of Boston, PHT reviewed the last few years of growth in the electronic patient-reported outcome (ePRO) niche. Business has been…more...
With the basic features and functions in place, many providers of clinical trial software are busy refining the ways that users get information in and out. Reports have been newly modernized…more...
Major electronic diary providers all built their platforms around a Windows or Palm-based device that plugs into an electrical outlet. But that dependence on hardware is a bit cloudy going forward,…more...
In this election season, there are too many unkind jokes about politics being the second-oldest profession. But that jesting got us to wonder. What is the second-oldest clinical trial technology? Paper was invented in China two thousand years ago, so the second-oldest prize belongs to ... interactive voice response (IVR), which depends on a mundane bit of…more...
Safety. Efficacy. Are those two cardinal notions of clinical development enough? Jean Paty has a third. He believes it is as central as safety and efficacy. Paty is co-founder and senior VP of scientific, quality and regulatory affairs at invivodata, a Pittsburgh, Penn., electronic patient diary firm. If safety and efficacy are the X and Y axes…more...
Are patient-reported outcomes a growth industry? A business? Philadelphia's ERT apparently thinks so, having just paid $81 million for the clinical trial business of Carefusion. The purchase could increase ERT's revenue by 50 percent, to perhaps $150 million yearly. That would put it in the general ballpark of the sales at Parexel's technology division or …more...
After doing 20 trials together, Quintiles and ediary supplier invivodata announced a closer partnership. For the large contract research organization, the relationship likely brings additional scientific firepower to a research niche newly legitimized by a final FDA guidance document in patient reported outcomes (PRO). For the Pittsburgh ediary supplier, meanwhile, the relationship will bring more projects and…more...
PHT discusses the growth in the acceptance of ePRO as a core technology.
The Mayo Clinic’s Jeff Sloan discusses where the field of patient-reported outcomes has come from and where it could be headed.
In the first of a ClinPage series, a sense of the centrality of the patient—and new levels of comfort with tools for electronic patient-reported outcomes (ePRO).
The technology firms have simplified the ways that customers can pass data from two systems to a third.
The Boston patient-reported outcome firm discusses ways to make running diary projects a bit easier.
The two Boston-area firms appear headed for a more intense IVR rivalry.
Rachael King, the new head of patient diary firm CRF, discusses trends and a robust pipeline.
Organizations
Conferences
Info & Opinion
© 2013 ClinPage. All Rights Reserved.